StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
257
This month
15
This week
3
This year
31
Yesterday
1
Publishing Date
2024 - 04 - 15
2
2024 - 04 - 11
2
2024 - 04 - 08
4
2024 - 04 - 05
2
2024 - 03 - 27
2
2024 - 03 - 12
2
2024 - 01 - 29
2
2023 - 11 - 02
2
2023 - 10 - 30
2
2023 - 10 - 26
2
2023 - 10 - 23
3
2023 - 10 - 16
2
2023 - 10 - 10
2
2023 - 10 - 05
3
2023 - 09 - 26
2
2023 - 09 - 18
2
2023 - 09 - 12
3
2023 - 09 - 11
2
2023 - 08 - 29
2
2023 - 08 - 08
3
2023 - 07 - 24
2
2023 - 07 - 17
4
2023 - 07 - 03
2
2023 - 06 - 28
2
2023 - 06 - 26
2
2023 - 06 - 05
2
2023 - 06 - 02
2
2023 - 05 - 22
2
2023 - 05 - 17
2
2023 - 05 - 16
5
2023 - 05 - 09
2
2022 - 10 - 31
3
2022 - 09 - 30
2
2022 - 09 - 16
2
2022 - 08 - 25
2
2022 - 08 - 08
2
2021 - 09 - 27
2
2021 - 09 - 20
3
2021 - 09 - 16
2
2021 - 09 - 13
2
2021 - 06 - 21
2
2021 - 06 - 11
1
2021 - 06 - 10
2
2021 - 06 - 09
1
2021 - 06 - 08
1
2021 - 06 - 01
2
2021 - 05 - 26
1
2021 - 05 - 20
1
2021 - 05 - 04
1
2021 - 04 - 26
1
2021 - 04 - 23
1
2021 - 04 - 19
1
2021 - 03 - 31
1
2021 - 03 - 26
1
2021 - 03 - 24
1
2021 - 03 - 18
1
2021 - 03 - 17
1
2021 - 03 - 16
1
2021 - 03 - 15
1
2021 - 01 - 18
1
Sector
Commercial services
1
Communications
6
Consumer durables
2
Consumer non-durables
5
Consumer services
3
Electronic technology
7
Energy minerals
4
Finance
11
Health care and social assistance
1
Health services
1
Health technology
140
Industrial services
1
Manufacturing
22
Mining, quarrying, and oil and gas extraction
1
N/a
15
Non-energy minerals
19
Process industries
4
Producer manufacturing
2
Professional, scientific, and technical services
10
Real estate and rental and leasing
1
Retail trade
3
Technology services
7
Utilities
2
Tags
Acquire
3
Acquisition
3
Alzheimer’s
4
Antibody
4
Atopic dermatitis
4
Biopharma
5
Cancer
10
Candidate
9
Cell
6
Chmp
5
Clinical-trials-phase-i
5
Clinical-trials-phase-ii
7
Clinical-trials-phase-iii
8
Contract
6
Covid
4
Covid-19
8
Depression
4
Dermatitis
7
Designation
5
Diabetic
4
Disease
15
Expansion
4
Financial
4
Global
7
Growth
7
Leukemia
5
Life
4
Macular
4
Market
6
Meeting
8
N/a
211
Ongoing
11
Pharm-country
4
Pharma
5
Pharmaceuticals
10
Phase 1
15
Phase 2
17
Phase 2b
6
Phase 3
14
Pneumococcal
5
Positive
221
Potential
4
Preclinical
5
Presentation
4
Report
5
Research
5
Response
4
Results
91
Schizophrenia
5
Solutions
4
Study
34
Therapeutics
26
Therapy
7
Topline
41
Treatment
30
Trial
68
Trials
5
Update
7
Vaccine
14
Year
4
Entities
3m company
1
4d molecular therapeutics inc
1
89bio, inc.
1
Acadia pharmaceuticals inc.
1
Acelyrin, inc.
1
Aclaris therapeutics, inc.
2
Actinium pharmaceuticals, inc.
2
Affimed n.v.
2
Agios pharmaceuticals, inc.
2
Apellis pharmaceuticals, inc.
2
Arrival
2
Aslan pharmaceuticals limited
2
Autolus therapeutics plc
2
Beigene, ltd.
2
Beyondspring, inc.
2
Biontech se
5
Bioxcel therapeutics, inc.
3
Bright minds biosciences inc
2
Connect biopharma holdings ltd - adr
2
Cyclerion therapeutics, inc.
2
Digihost technology inc.
2
Eldorado gold corporation
2
Eli lilly and company
4
Emergent biosolutions, inc.
2
Endeavour silver corporation
2
First majestic silver corp.
2
First mining gold corp.
2
Hubspot, inc.
2
Immunic, inc.
2
Invivyd inc
2
Ionis pharmaceuticals, inc.
3
Karuna therapeutics, inc.
2
Kering
3
Lipocine inc.
2
Matinas biopharma holdings, inc.
2
Mediwound ltd.
2
Merck & company, inc.
6
Nrx pharmaceuticals inc
2
Ocugen, inc.
2
Oculis holding ag
5
Orange
6
Paramount gold nevada corp.
2
Parsons corporation
4
Pfizer, inc.
11
Praxis precision medicines, inc.
4
Roivant sciences ltd.
2
Sanofi
6
Sutro biopharma, inc.
2
Syndax pharmaceuticals, inc.
2
Synlogic, inc.
2
Target hospitality corp.
2
Tff pharmaceuticals, inc.
2
Tiziana life sciences plc
2
Transcode therapeutics inc
2
Treasury metals inc
2
Trimble inc.
3
Vaxcyte, inc.
2
Veru inc.
2
Vyne therapeutics inc.
2
Yamana gold inc.
2
Symbols
ABOS
1
ACAD
1
ACET
1
ACRS
2
AFMD
2
AG
2
AGIO
2
APLS
2
ARVL
2
ASLN
2
ATNM
2
AUTL
2
AUY
2
BGNE
2
BNTX
5
BTAI
3
BYSI
2
CNTB
2
CYCN
2
DGHI
2
DRUG
2
EBS
2
EGO
2
EXK
2
FFMGF
2
FNCTF
6
HUBS
2
IMUX
2
IONS
3
IVVD
2
KRTX
2
LLY
4
LPCN
2
MDWD
2
MRK
6
MTNB
2
NRXP
2
OCGN
2
OCS
5
PCVX
2
PFE
11
PPRUF
3
PPRUY
3
PRAX
4
PSN
4
PZG
2
RNAZ
2
ROIV
2
SNDX
2
SNY
6
SNYNF
4
STRO
2
SYBX
2
TFFP
2
TH
2
TLSA
2
TRMB
3
TSRMF
2
VERU
2
VYNE
2
Exchanges
Amex
14
Nasdaq
198
Nyse
63
Crawled Date
2024 - 04 - 15
2
2024 - 04 - 11
2
2024 - 04 - 08
4
2024 - 04 - 05
2
2024 - 03 - 27
2
2024 - 03 - 12
2
2024 - 01 - 29
2
2023 - 11 - 02
2
2023 - 10 - 30
2
2023 - 10 - 26
2
2023 - 10 - 23
3
2023 - 10 - 16
2
2023 - 10 - 10
2
2023 - 10 - 05
3
2023 - 09 - 26
2
2023 - 09 - 18
2
2023 - 09 - 12
3
2023 - 09 - 11
2
2023 - 08 - 29
2
2023 - 08 - 08
3
2023 - 07 - 24
2
2023 - 07 - 17
4
2023 - 07 - 03
2
2023 - 06 - 28
2
2023 - 06 - 26
2
2023 - 06 - 05
2
2023 - 06 - 02
2
2023 - 05 - 22
2
2023 - 05 - 17
2
2023 - 05 - 16
5
2023 - 05 - 09
2
2022 - 10 - 31
3
2022 - 09 - 30
2
2022 - 09 - 16
2
2022 - 08 - 25
2
2022 - 08 - 08
2
2021 - 09 - 27
2
2021 - 09 - 20
3
2021 - 09 - 16
2
2021 - 09 - 13
2
2021 - 06 - 21
2
2021 - 06 - 11
1
2021 - 06 - 10
2
2021 - 06 - 09
1
2021 - 06 - 08
1
2021 - 06 - 01
2
2021 - 05 - 26
1
2021 - 05 - 20
1
2021 - 05 - 04
1
2021 - 04 - 26
1
2021 - 04 - 23
1
2021 - 04 - 19
1
2021 - 03 - 31
1
2021 - 03 - 26
1
2021 - 03 - 24
1
2021 - 03 - 18
1
2021 - 03 - 17
1
2021 - 03 - 16
1
2021 - 03 - 15
1
2021 - 01 - 18
1
Crawled Time
00:00
58
00:20
13
01:00
31
02:00
16
03:00
11
04:00
10
04:20
6
05:00
18
06:00
43
07:00
50
08:00
46
08:20
7
09:00
46
10:00
41
11:00
257
11:01
3
11:03
2
12:00
519
12:01
5
12:03
8
12:04
2
12:07
2
12:15
42
12:20
117
12:30
74
12:58
2
13:00
357
13:01
5
13:02
3
13:05
2
13:07
2
13:14
2
13:15
30
13:20
82
13:30
82
13:35
2
14:00
230
14:01
9
14:15
20
14:20
46
14:30
43
15:00
134
15:15
7
15:20
22
15:30
36
16:00
86
16:01
3
16:20
36
17:00
112
18:00
84
19:00
60
20:00
124
20:20
25
21:00
166
21:06
5
22:00
149
22:01
3
22:12
3
22:13
5
23:00
90
Source
ir.biolinerx.com
1
ir.cyclerion.com
2
ir.kalvista.com
1
mindmed.co
1
piedmontlithium.com
1
spacfeed.com
2
www.aslanpharma.com
1
www.beyondspringpharma.com
2
www.biospace.com
46
www.globenewswire.com
143
www.hubspot.com
2
www.paramountnevada.com
1
www.parsons.com
1
www.prnewswire.com
52
www.vbivaccines.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
positive
crawled time :
11:00
save search
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Published:
2024-04-16
(Crawled : 11:00)
- globenewswire.com
ITCI
|
$76.68
-3.96%
-4.12%
2.9M
|
Health Technology
|
21.69%
|
O:
14.75%
H:
12.75%
C:
6.04%
positive
topline
therapy
results
study
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Published:
2024-04-15
(Crawled : 11:00)
- globenewswire.com
RARE
|
$44.11
4.25%
4.08%
890K
|
Health Technology
|
-15.25%
|
O:
-10.79%
H:
0.0%
C:
-3.75%
gtx-102
positive
treatment
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
Published:
2024-04-15
(Crawled : 11:00)
- globenewswire.com
TFFP
|
$3.31
-9.69%
22K
|
Health Technology
|
-16.62%
|
O:
0.25%
H:
1.26%
C:
-11.56%
tacrolimus
presentation
positive
sessions
pharmaceuticals
trial
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Published:
2024-04-11
(Crawled : 11:00)
- globenewswire.com
IPSC
|
$2.825
-10.03%
-11.15%
180K
|
Professional, Scientific, and T...
|
-18.23%
|
O:
3.39%
H:
11.53%
C:
2.02%
disease
million
pipeline
acquisition
expansion
therapeutics
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
Published:
2024-04-11
(Crawled : 11:00)
- prnewswire.com
MS
3 d
|
$90.08
1.06%
-0.28%
9.5M
|
Finance
|
-2.14%
|
O:
-0.74%
H:
0.09%
C:
-5.32%
LPCN
|
$4.76
-10.46%
34K
|
Health Technology
|
-19.32%
|
O:
6.78%
H:
13.49%
C:
1.75%
obesity
positive
results
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Published:
2024-04-10
(Crawled : 11:00)
- globenewswire.com
OCGN
|
$1.44
-9.43%
-10.42%
7.2M
|
Health Technology
|
-7.02%
|
O:
2.92%
H:
3.41%
C:
2.27%
ocu400
approval
positive
for
therapy
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
Published:
2024-04-08
(Crawled : 11:00)
- globenewswire.com
INZY
|
$4.65
-4.12%
-4.3%
410K
|
Health Technology
|
-23.74%
|
O:
2.2%
H:
7.69%
C:
-9.69%
inz-701
pharma
positive
ongoing
trials
topline
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
Published:
2024-04-08
(Crawled : 11:00)
- prnewswire.com
SNDX
|
$20.75
-2.49%
-2.55%
1.7M
|
Health Technology
|
-4.87%
|
O:
3.35%
H:
0.0%
C:
-1.34%
gment-101
positive
leukemia
trial
DPC Dash - Domino's Pizza China Strengthened its Unique Positioning in China's Pizza Market in 2023
Published:
2024-04-08
(Crawled : 11:00)
- prnewswire.com
DPZ
|
$482.05
-0.95%
0.0%
330K
|
Consumer Services
|
0.02%
|
O:
1.28%
H:
2.12%
C:
1.87%
pizza
unique
china
market
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Published:
2024-04-08
(Crawled : 11:00)
- biospace.com/
OCS
3 d
|
$11.99
-0.08%
-0.08%
33K
|
n/a
|
7.24%
|
O:
0.36%
H:
0.18%
C:
-2.76%
ocs-01
positive
treatment
for
meeting
trial
results
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
Published:
2024-04-05
(Crawled : 11:00)
- globenewswire.com
OCGN
|
$1.44
-9.43%
-10.42%
7.2M
|
Health Technology
|
1.92%
|
O:
1.92%
H:
0.0%
C:
0.0%
ocu410
armada
review
positive
for
study
HUB Cyber Security Secures $8 Million in Financing to Accelerate Growth and Strengthen Financial Position
Published:
2024-04-05
(Crawled : 11:00)
- globenewswire.com
HUBC
|
$1.35
-27.42%
-37.78%
6.7M
|
n/a
|
126.86%
|
O:
78.07%
H:
28.77%
C:
5.48%
million
security
financial
growth
ZeroFox Wins Multiple Industry Awards and Reinforces Digital Risk Protection Leadership Position
Published:
2024-04-04
(Crawled : 11:00)
- globenewswire.com
ZFOX
|
$1.125
-0.44%
-0.44%
43K
|
|
0.0%
|
O:
0.0%
H:
0.0%
C:
0.0%
risk
awards
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Published:
2024-04-02
(Crawled : 11:00)
- globenewswire.com
ROIV
|
$10.45
-2.43%
-2.49%
4M
|
Manufacturing
|
2.68%
|
O:
4.79%
H:
3.02%
C:
-0.09%
pharma
million
authorization
positive
repurchase
results
study
Digihost Announces 60% Month-Over-Month Increase in Cash and Crypto Position and Provides March 2024 Production Update
Published:
2024-04-01
(Crawled : 11:00)
- globenewswire.com
DGHI
|
$1.28
-5.19%
-5.47%
160K
|
n/a
|
1.44%
|
O:
5.76%
H:
0.0%
C:
-2.72%
update
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
Published:
2024-03-27
(Crawled : 11:00)
- globenewswire.com
ALT
|
$7.05
-6.25%
-6.67%
3.6M
|
Commercial Services
|
-13.06%
|
O:
7.63%
H:
3.33%
C:
-4.51%
year
positive
financial
results
atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
Published:
2024-03-27
(Crawled : 11:00)
- globenewswire.com
ATAI
|
$1.98
-7.91%
-8.59%
1.5M
|
Manufacturing
|
24.28%
|
O:
4.05%
H:
1.11%
C:
-0.56%
bpl-003
label
life
positive
depression
treatment
sciences
results
study
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
Published:
2024-03-26
(Crawled : 11:00)
- globenewswire.com
PRAX
|
$50.59
-3.47%
-3.6%
270K
|
Health Technology
|
3.78%
|
O:
19.9%
H:
11.0%
C:
2.69%
prax-628
precision
positive
photo
response
results
study
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
Published:
2024-03-20
(Crawled : 11:00)
- globenewswire.com
SLRN
|
$5.02
-2.34%
-2.39%
600K
|
|
-35.43%
|
O:
2.39%
H:
5.4%
C:
2.09%
first
disease
positive
thyroid
eye
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
Published:
2024-03-14
(Crawled : 11:00)
- globenewswire.com
IMRX
|
$1.865
1.36%
1.34%
300K
|
|
-68.71%
|
O:
-21.09%
H:
7.96%
C:
-37.5%
tumors
positive
topline
trial
results
← Previous
1
2
3
4
5
6
7
8
9
…
12
13
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.